Novo Nordisk expanded a deal with Valo Health to discover and develop treatments for obesity, type 2 diabetes and ...

AI technologies are revolutionizing healthcare, driving personalized care, efficient health management, and faster drug ...

Under the expanded collaboration, Valo's Opal Computational Platform will be integrated with Novo Nordisk's expertise in cardiometabolic diseases, deriving insights from real-world patient data, ...

Scope of collaboration originally signed in 2023 will significantly expand to enable the discovery and development of up to 20 novel drug ...

SAN FRANCISCO, Jan. 10, 2025 /PRNewswire/ -- Psylo, a leader in neurotherapeutics discovery and development, has officially rebranded as Xylo Bio. This transformation reflects the company's growth, ...

GSK took center stage last month, forming standout partnerships and alliances across multiple therapeutic areas.

Novo Nordisk and Valo Health have expanded their 16-month-old collaboration into an up-to-$4.6 billion-plus artificial ...

Company to Host International Roadshow the Week of January 13, 2025 LOS ANGELES, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: ...

This dynamic field has seen tremendous change in recent years. Leaders share their perspectives on what trends we can expect ...

USA Molecular Weight Marker Market is expected to show increasing and is expected to grow at a CAGR of ~$% from 2022 to 2028 with increasing innovations in the life sciences & personalized medicine.